Understand the source comparison
Cartalax Results Timeline: Research Phase Comparison
Before starting any Cartalax research protocol, understanding the expected timeline for different outcome categories prevents premature termination and ensures sufficient observation windows for meaningful data collection. The following table maps research pha
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before starting any Cartalax research protocol, understanding the expected timeline for different outcome categories prevents premature termination and ensures sufficient observation windows for meaningful data collection. The following table maps research phases to expected biomarker changes based on published preclinical models.
- Phase 1: Early Engagement
- Weeks 0–4
- Gene expression changes (MUC5AC, MUC6 upregulation); no structural tissue changes yet measurable
- RT-PCR for mucin gene expression; subjective symptom logs
- Too early for conclusive assessment. Baseline data collection phase. Subjective improvements possible but not reliable indicators of structural effect.
- Phase 2: Functional Translation
- Weeks 4–8
- Increased mucin secretion; improved gastric motility; subjective symptom improvement in 40–60% of models
- PAS staining for mucin; gastric emptying studies; symptom scoring
- First measurable functional benefits emerge. Subjective markers correlate moderately with objective mucin production. Optimal time for interim assessment.
- Phase 3: Structural Remodeling
- Weeks 8–16
- Mucin layer thickness increase (30–50% vs baseline); epithelial proliferation rate normalization; tight junction protein expression improvement
- Histological analysis (H&E, immunohistochemistry for Ki-67, occludin, ZO-1); mucin layer thickness measurement
- Critical outcome window. Statistically significant tissue-level changes measurable via histology. Protocols terminated before week 12 miss this phase entirely.
- Phase 4: Sustained Benefit
- Weeks 16–20+
- Maintenance of improved tissue architecture; incremental gains diminish; plateau typically reached by week 20
- Repeat histology; long-term symptom tracking; mucin gene expression stability
- Plateau phase. Continued dosing maintains benefit but additional structural improvement minimal. Consider washout and re-assessment to determine durability.
- Post-Protocol Washout
- Weeks 20–24 (4 weeks post-cessation)
- Gradual return toward baseline in some markers; mucin layer thickness may partially regress; individual variability high
- Follow-up histology at 4 weeks post-treatment; symptom recurrence monitoring
- Durability assessment. Some structural changes persist; others regress. Informs need for maintenance dosing or repeat cycles.